Asset Details
Do you wish to reserve the book?
Updated UK Recommendations for HER2 assessment in breast cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Updated UK Recommendations for HER2 assessment in breast cancer
Do you wish to request the book?
Updated UK Recommendations for HER2 assessment in breast cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Updated UK Recommendations for HER2 assessment in breast cancer
2015
Overview
Human epidermal growth factor receptor 2 (HER2) overexpression is present in approximately 15% of early invasive breast cancers, and is an important predictive and prognostic marker. The substantial benefits achieved with anti-HER2 targeted therapies in patients with HER2-positive breast cancer have emphasised the need for accurate assessment of HER2 status. Current data indicate that HER2 test accuracy improved following previous publication of guidelines and the implementation of an external quality assessment scheme with a decline in false-positive and false-negative rates. This paper provides an update of the guidelines for HER2 testing in the UK. The aim is to further improve the analytical validity and clinical utility of HER2 testing by providing guidelines of test performance parameters, and recommendations on the postanalytical interpretation of test results. HER2 status should be determined in all newly diagnosed and recurrent breast cancers. Testing involves immunohistochemistry with >10% complete strong membrane staining defining a positive status. In situ hybridisation, either fluorescent or bright field chromogenic, is used either upfront or in immunohistochemistry borderline cases to detect the presence of HER2 gene amplification. Situations where repeat HER2 testing is advised are outlined and the impact of genetic heterogeneity is discussed. Strict quality control and external quality assurance of validated assays are essential. Testing laboratories should perform ongoing competency assessment and proficiency tests and ensure the reliability and accuracy of the assay. Pathologists, oncologists and surgeons involved in test interpretation and clinical use should adhere to published guidelines and maintain accurate performance and consistent interpretation of test results.
Publisher
BMJ Publishing Group LTD,BMJ Publishing Group
Subject
Antineoplastic Agents - therapeutic use
/ Audits
/ Biomarkers, Tumor - analysis
/ Biomarkers, Tumor - genetics
/ Biopsy
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - enzymology
/ Breast Neoplasms - pathology
/ Female
/ Gene Expression Regulation, Neoplastic
/ Humans
/ Immunohistochemistry - standards
/ In Situ Hybridization - standards
/ In Situ Hybridization, Fluorescence - standards
/ Quality Indicators, Health Care - standards
/ Receptor, ErbB-2 - antagonists & inhibitors
/ Specimen Handling - standards
/ Tumors
/ Workflow
